Monday, 31 August 2026European Markets

MAUNA KEA TECH Stock Bullish Momentum With A 17.42% Rise Before The Weekend

Loading stream...

(vianews) - the market ended the session with mauna kea tech (mkea.pa) rising 17.42% to €0.70 on friday, after two sequential sessions in a row of losses. cac 40 jumped 0.51% to €7,577.00, following the last session's downward trend on what was a somewhat positive trend exchanging session today.

mauna kea tech's last close was €0.60, 39.9% below its 52-week high of €0.99.

about mauna kea tech

mauna kea technologies sa develops and markets medical devices in europe and internationally. the company designs, develops, and markets tools to visualize and detect cell abnormalities in real time during standard gastrointestinal and pulmonary endoscopy procedures. its flagship product is cellvizio, a confocal miniprobe endomicroscopy system which provides physicians and researchers high-resolution images of tissues at the cellular level. the company was incorporated in 2000 and is headquartered in paris, france.

earnings per share

as for profitability, mauna kea tech has a trailing twelve months eps of €-0.27.

yearly top and bottom value

mauna kea tech's stock is valued at €0.70 at 22:34 est, way under its 52-week high of €0.99 and way above its 52-week low of €0.37.

moving average

mauna kea tech's worth is way higher than its 50-day moving average of €0.51 and way higher than its 200-day moving average of €0.58.

more news about mauna kea tech (mkea.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com